scholarly journals Natural‐killer and plasma cell infiltration are associated with a distinct immune subset in non‐small cell lung cancer

2021 ◽  
Author(s):  
Max Backman ◽  
Linnéa La Fleur ◽  
Pinja Kurppa ◽  
Dijana Djureinovic ◽  
Hedvig Elfving ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Natural Killer ◽  
Plasma Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cell Infiltration ◽  
Small Cell Lung ◽  
Plasma Cell Infiltration ◽  
Immune Subset

scholarly journals Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer

2018 ◽  
Vol 8 (2) ◽  
pp. e1527498 ◽  
Author(s):  
Emilie Picard ◽  
Yann Godet ◽  
Caroline Laheurte ◽  
Magalie Dosset ◽  
Jeanne Galaine ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Natural Killer Cells ◽  
Small Cell Lung Cancer ◽  
Natural Killer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Killer Cells ◽  
Regulatory Property

scholarly journals Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4037
Author(s):  
Pankaj Ahluwalia ◽  
Meenakshi Ahluwalia ◽  
Ashis K. Mondal ◽  
Nikhil S. Sahajpal ◽  
Vamsi Kota ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dendritic Cells ◽  
Tumor Microenvironment ◽  
Small Cell Lung Cancer ◽  
Nk Cells ◽  
Natural Killer ◽  
Cell Lung Cancer ◽  
Immune Cells ◽  
Small Cell ◽  
Small Cell Lung

Non-small cell lung cancer (NSCLC) is a major subtype of lung cancer that accounts for almost 85% of lung cancer cases worldwide. Although recent advances in chemotherapy, radiotherapy, and immunotherapy have helped in the clinical management of these patients, the survival rate in advanced stages remains dismal. Furthermore, there is a critical lack of accurate prognostic and stratification markers for emerging immunotherapies. To harness immune response modalities for therapeutic benefits, a detailed understanding of the immune cells in the complex tumor microenvironment (TME) is required. Among the diverse immune cells, natural killer (NK cells) and dendritic cells (DCs) have generated tremendous interest in the scientific community. NK cells play a critical role in tumor immunosurveillance by directly killing malignant cells. DCs link innate and adaptive immune systems by cross-presenting the antigens to T cells. The presence of an immunosuppressive milieu in tumors can lead to inactivation and poor functioning of NK cells and DCs, which results in an adverse outcome for many cancer patients, including those with NSCLC. Recently, clinical intervention using modified NK cells and DCs have shown encouraging response in advanced NSCLC patients. Herein, we will discuss prognostic and predictive aspects of NK cells and DC cells with an emphasis on NSCLC. Additionally, the discussion will extend to potential strategies that seek to enhance the anti-tumor functionality of NK cells and DCs.

Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance

Lung Cancer ◽  
2018 ◽  
Vol 120 ◽  
pp. 113-121 ◽  
Author(s):  
Meijun Du ◽  
Jonathan Thompson ◽  
Hannah Fisher ◽  
Peng Zhang ◽  
Chiang-Ching Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Plasma Cell ◽  
Cell Lung Cancer ◽  
Clinical Relevance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Genomic Alterations

Abstract 2303: Innate immunity driving tumor angiogenesis: the role of natural killer cells in non small cell lung cancer (NSCLC) .

2013 ◽  
Author(s):  
Adriana Albini ◽  
Antonino Bruno ◽  
Arianna Pagani ◽  
Andrea Imperatori ◽  
Marco Spagnoletti ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Innate Immunity ◽  
Natural Killer Cells ◽  
Small Cell Lung Cancer ◽  
Natural Killer ◽  
Cell Lung Cancer ◽  
Tumor Angiogenesis ◽  
Small Cell ◽  
Small Cell Lung

Abstract 5395: Genomic variations in plasma cell free DNA from small cell lung cancer

2017 ◽  
Author(s):  
Meijun Du ◽  
Hannah Fisher ◽  
Peng Zhang ◽  
Huijuan Zhang ◽  
Liang Wang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Plasma Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Free Dna ◽  
Genomic Variations ◽  
Free Dna

scholarly journals Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells

Blood ◽  
1985 ◽  
Vol 65 (3) ◽  
pp. 764-768 ◽  
Author(s):  
PA Jr Bunn ◽  
I Linnoila ◽  
JD Minna ◽  
D Carney ◽  
AF Gazdar
Keyword(s):  
Lung Cancer ◽  
Natural Killer Cells ◽  
Small Cell Lung Cancer ◽  
Natural Killer ◽  
Cell Lung Cancer ◽  
Endocrine Cells ◽  
Small Cell ◽  
Small Cell Lung ◽  
Killer Cells ◽  
Leu 7

Abstract Small cell lung cancer is distinguished from other lung cancer histologic types by possessing a variety of neuroendocrine properties. Anti-Leu-7 is a monoclonal antibody that recognizes a 110,000-dalton molecular weight glycoprotein initially described on natural killer cells and subsequently reported on a variety of normal and malignant neural and neuroendocrine cell types. We have found intense anti-Leu-7 binding to a large number of small cell lung cancers, while other lung cancer types were negative or showed only weak and focal binding. Other antigens expressed by natural killer cells, lymphocytes, and monocytes were never or less often expressed on small cell lung cancer cells. In addition, we report for the first time anti-Leu-7 binding by carcinoids, carotid body tumors, pheochromocytomas, endocrine cells of the fetal bronchus and the adult intestine, and select pancreatic islet cells. Anti-Leu-7 binding by small cell lung cancer is consistent with a derivation from pulmonary precursor cells, and anti-Leu-7 staining is clinically useful for the identification of human neuroendocrine tumors of the amine precursor uptake and decarboxylation (“APUD”) type.

scholarly journals Prognostic significance of peripheral CD8+CD28+ and CD8+CD28− T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Chao Liu ◽  
Wang Jing ◽  
Ning An ◽  
Aijie Li ◽  
Weiwei Yan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Small Cell Lung Cancer ◽  
Natural Killer ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Small Cell Lung ◽  
Radio Therapy ◽  
Nsclc Patients

Abstract Background Noninvasive prognostic biomarkers are needed for advanced non-small cell lung cancer (NSCLC) patients with different histological types to identify cases with poor survival. Here, we investigated the prognostic values of peripheral CD8+CD28+ T cells and CD8+CD28− T cells in advanced NSCLC patients treated with chemo(radio)therapy and the impact of histological type on them. Methods Of 232 registered advanced NSCLC patients, 101 treatment-naïve individuals were eligible and included in our study. Flow cytometry was used to evaluate CD8+CD28+ T cells, CD8+CD28− T cells, CD4+ CD25hi T cells, B cells, natural killer cells, γδT cells, and natural killer T cells in patients’ peripheral blood. Results The median follow-up time was 13.6 months. Fifty-nine (58.4%) patients died by the end of our study. Fifty-three of the 101 advanced NSCLC cases selected for our study were adenocarcinomas (ADs), and 48 were squamous cell carcinomas (SCCs). Multivariate analyses showed that increased levels of CD8+CD28+ T cells independently predicted favorable overall survival (OS) [hazard ratio (HR): 0.51, 95% confidence interval (CI) 0.30–0.89, P = 0.021] and progression-free survival (PFS) (HR: 0.66, 95% CI 0.37–0.93, P = 0.038) in ADs, but the prediction in SCCs was not statistically significant. In contrast, high levels of CD8+CD28− T cells independently predicted unfavorable OS (HR: 1.41, 95% CI 1.17–3.06, P = 0.035) and PFS (HR: 2.01, 95% CI 1.06–3.85, P = 0.029) in SCCs, but the prediction in ADs was not statistically significant. ADs had higher levels of CD4+CD25hi T cells and CD8+CD28− T cells and lower NK cells (all P < 0.05) than SCCs. Conclusions Our findings uncovered the prognostic values of peripheral CD8+CD28+ T cells and CD8+CD28− T cells in advanced NSCLC patients treated with chemo(radio)therapy, which could help to identify patients with poor outcomes and refine treatment strategies.

scholarly journals Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer

Oncotarget ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 2771-2780 ◽  
Author(s):  
Shaohua Cui ◽  
Wei Zhang ◽  
Liwen Xiong ◽  
Feng Pan ◽  
Yanjie Niu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Small Cell Lung Cancer ◽  
Plasma Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Next Generation ◽  
Small Cell Lung ◽  
Free Dna ◽  
Generation Sequencing

Increase of spontaneous lung metastasis of small cell lung cancer in the absence of Natural Killer cells in Pfp/Rag2 double knock out mice

Pneumologie ◽  
2008 ◽  
Vol 62 (S 2) ◽  
Author(s):  
S Sodeur ◽  
S Ullrich ◽  
H Gustke ◽  
U Zangemeister-Wittke ◽  
U Schumacher
Keyword(s):  
Lung Cancer ◽  
Natural Killer Cells ◽  
Small Cell Lung Cancer ◽  
Natural Killer ◽  
Lung Metastasis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Knock Out ◽  
Knock Out Mice
Sign in / Sign up

Export Citation Format

Share Document